J059: CD22-targeting immunotoxin initiates systemic anti-lymphoma immunity in syngeneic mice
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.07.2017
End date : 30.06.2020
Project details
Scientific Abstract
Preclinical and first clinical data suggest that treatment with recombinant immunotoxin (rITs) targeting mesothelin induced anti-tumor immunity in patients. The goal of this study is to test CD22-targeting rITs for their capacity of inducing anti-lymphoma immunity in a newly established syngeneic mouse model. The model will be used to understand molecular mechanisms central to the lymphoma-host-interaction and to optimize immune-modulating combination treatment based on lymphoma-targeting rITs.
Involved:
Contributing FAU Organisations:
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Department of Medicine 5 – Haematology and Oncology
Medizinische Fakultät
